Iambic Therapeutics Finalizes $150M IPO at $16/Share, Lists on Nasdaq as IAM
IAM is trading near its 52-week low of $16.15 (15% above the low).
Summary
Iambic Therapeutics priced its IPO at $16.00 per share, raising $150 million gross and listing on Nasdaq as 'IAM.' The net proceeds of ~$135 million fund clinical development of its HER2 inhibitor and two earlier programs, with cash runway into Q4 2028.
Key Events · Financing and Capital Events · IAM
-
IPO Priced at $16.00/Share
9,375,000 shares sold at $16.00, the midpoint of the $15-$17 range, raising $150 million gross and $135 million net after $10.5 million in underwriting discounts and $4.5 million in estimated expenses.
-
Use of Proceeds Detailed
Approximately $75 million for IAM1363 clinical development, $15 million for IAM217, $15 million for IAM-C1, $20 million for platform investment, and the remainder for working capital.
-
Cash Runway Into Q4 2028
Existing cash of $207.9 million as of June 30, 2026, plus net IPO proceeds, is expected to fund operations into or through the fourth quarter of 2028.
-
Immediate Dilution to New Investors
Purchasers at $16.00 per share face immediate dilution of $8.35 per share in pro forma as adjusted net tangible book value, which is $7.65 per share after the offering.
Analysis · IAM · Life Sciences
The final prospectus confirms Iambic's IPO priced at $16.00 per share, the midpoint of its $15-$17 range, raising $150 million gross ($135 million net) and listing on Nasdaq under 'IAM.' The company is a clinical-stage AI-driven drug discovery firm with a lead HER2 inhibitor (IAM1363) in Phase 1/1b and two earlier programs. The offering provides cash runway into or through Q4 2028, funding IAM1363 through a potential registrational trial, IAM217 and IAM-C1 into Phase 1/2, and continued platform investment. New investors face immediate dilution of $8.35 per share in pro forma net tangible book value, and the $66.5 million convertible notes convert into 4.95 million shares at the IPO price. The deal's successful pricing at the midpoint, with indications of interest from ARK and Duquesne for up to $60 million, suggests solid institutional demand for this AI-biotech story.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 36.7% of the 962 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IAM was trading at $18.51 on NASDAQ in the Life Sciences sector. The 52-week trading range was $16.15 to $19.70. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.